AlphaCentric Advisors LLC Decreases Holdings in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)

AlphaCentric Advisors LLC decreased its position in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) by 29.7% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 45,000 shares of the company’s stock after selling 19,000 shares during the quarter. Mirum Pharmaceuticals accounts for about 1.3% of AlphaCentric Advisors LLC’s holdings, making the stock its 23rd biggest position. AlphaCentric Advisors LLC owned about 0.09% of Mirum Pharmaceuticals worth $1,755,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Quest Partners LLC boosted its stake in shares of Mirum Pharmaceuticals by 7,513.3% during the 2nd quarter. Quest Partners LLC now owns 1,142 shares of the company’s stock worth $39,000 after acquiring an additional 1,127 shares in the last quarter. Amalgamated Bank lifted its stake in Mirum Pharmaceuticals by 60.8% in the 2nd quarter. Amalgamated Bank now owns 1,357 shares of the company’s stock valued at $46,000 after buying an additional 513 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its stake in Mirum Pharmaceuticals by 22.6% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,725 shares of the company’s stock valued at $67,000 after buying an additional 318 shares in the last quarter. ProShare Advisors LLC purchased a new stake in Mirum Pharmaceuticals in the 2nd quarter valued at approximately $213,000. Finally, Creative Planning purchased a new stake in Mirum Pharmaceuticals in the 3rd quarter valued at approximately $249,000.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on the company. Evercore ISI upped their target price on Mirum Pharmaceuticals from $62.00 to $66.00 and gave the company an “outperform” rating in a research note on Thursday, August 8th. Robert W. Baird upped their target price on Mirum Pharmaceuticals from $39.00 to $44.00 and gave the company an “outperform” rating in a research note on Thursday, August 8th. Cantor Fitzgerald upped their target price on Mirum Pharmaceuticals from $50.00 to $60.00 and gave the company an “overweight” rating in a research note on Thursday, August 8th. HC Wainwright reiterated a “buy” rating and issued a $66.00 price target on shares of Mirum Pharmaceuticals in a report on Friday, October 11th. Finally, Leerink Partners boosted their price target on Mirum Pharmaceuticals from $47.00 to $49.00 and gave the company an “outperform” rating in a report on Thursday, October 17th. Ten investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat, Mirum Pharmaceuticals presently has a consensus rating of “Buy” and an average target price of $56.82.

Mirum Pharmaceuticals Stock Up 0.1 %

MIRM stock opened at $40.45 on Tuesday. The company has a debt-to-equity ratio of 1.34, a quick ratio of 3.09 and a current ratio of 3.28. The business has a fifty day simple moving average of $40.10 and a 200-day simple moving average of $35.00. Mirum Pharmaceuticals, Inc. has a 52 week low of $23.14 and a 52 week high of $45.23.

Mirum Pharmaceuticals (NASDAQ:MIRM) last released its quarterly earnings data on Wednesday, August 7th. The company reported ($0.52) EPS for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.05). The firm had revenue of $77.90 million for the quarter, compared to analyst estimates of $75.03 million. Mirum Pharmaceuticals had a negative return on equity of 43.47% and a negative net margin of 40.34%. The company’s quarterly revenue was up 107.7% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.92) earnings per share. As a group, analysts predict that Mirum Pharmaceuticals, Inc. will post -1.84 earnings per share for the current year.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.